Novo Nordisk AS
(OCSE:NOVO B)
kr
775.8
18.5 (2.44%)
Market Cap: 3.45 Til
Enterprise Value: 3.43 Til
PE Ratio: 36.59
PB Ratio: 28.65
GF Score: 97/100 
Q3 2024 Novo Nordisk A/S Earnings Presentation (London-Based Investors) TranscriptNov 07, 2024- Q3 2024 Novo Nordisk A/S Earnings Call TranscriptNov 06, 2024kr749.5 (+0.55%)Earnings
- Q2 2024 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptAug 08, 2024kr864 (+4.30%)Earnings
- Q2 2024 Novo Nordisk A/S Earnings Call TranscriptAug 07, 2024kr828.4 (-6.71%)Earnings
- Q1 2024 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptMay 03, 2024kr850.6 (-2.58%)Earnings
- Q1 2024 Novo Nordisk A/S Earnings Call TranscriptMay 02, 2024kr873.1 (-2.74%)Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 21, 2024
- Novo Nordisk A/S Capital Markets Day TranscriptMar 07, 2024
- Q4 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptFeb 01, 2024kr786.4 (+1.50%)Earnings
- Q4 2023 Novo Nordisk A/S Earnings Call TranscriptJan 31, 2024kr774.8 (+3.56%)Earnings
- Novo Nordisk A/S at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- Novo Nordisk A/S at American Heart Association Conference TranscriptNov 11, 2023
- Q3 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptNov 03, 2023kr683.9 (-3.61%)Earnings
- Q3 2023 Novo Nordisk A/S Earnings Call TranscriptNov 02, 2023kr709.5 (+3.17%)Earnings
- Q2 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptAug 11, 2023kr620.6 (-0.54%)Earnings
- Q2 2023 Novo Nordisk A/S Earnings Call TranscriptAug 10, 2023kr624 (-1.22%)Earnings
- Novo Nordisk A/S R&D Investor Call TranscriptJun 26, 2023
- Q1 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptMay 09, 2023kr570.9 (-0.37%)Earnings
- Q1 2023 Novo Nordisk A/S Earnings Call TranscriptMay 04, 2023kr547 (-2.60%)Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 23, 2023
- Q4 2022 Novo Nordisk A/S Earnings Call TranscriptFeb 01, 2023kr471.2 (-0.06%)Earnings
- Q3 2022 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptNov 03, 2022kr428.3 (-0.46%)Earnings
- Q3 2022 Novo Nordisk A/S Earnings Call TranscriptNov 02, 2022kr430.3 (+7.44%)Earnings
- Novo Nordisk A/S at JPMorgan CEO Call Series TranscriptSep 14, 2022
- Q2 2022 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptAug 05, 2022kr378 (-2.96%)Earnings
- Q2 2022 Novo Nordisk A/S Earnings Call TranscriptAug 03, 2022kr385.6 (-9.40%)Earnings
- Novo Nordisk A/S Investor and Analyst Event at ADA TranscriptJun 06, 2022
- Q1 2022 Novo Nordisk A/S Earnings Presentation - London TranscriptMay 05, 2022
- Q1 2022 Novo Nordisk A/S Earnings Call TranscriptApr 29, 2022kr406.15 (+5.38%)Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 24, 2022
- Novo Nordisk A/S Capital Markets Day TranscriptMar 03, 2022
- Q4 2021 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptFeb 04, 2022kr323.25 (-5.07%)Earnings
- Q4 2021 Novo Nordisk A/S Earnings Call TranscriptFeb 02, 2022kr350.25 (+4.37%)Earnings
- Novo Nordisk A/S to Discuss Supply Challenges for Wegovy Call TranscriptDec 20, 2021
- Q3 2021 Novo Nordisk A/S Earnings Presentation (London-Based Investors) TranscriptNov 04, 2021
- Q3 2021 Novo Nordisk A/S Earnings Call TranscriptNov 03, 2021kr365.8 (+2.46%)Earnings
- Q2 2021 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptAug 06, 2021kr313.45 (-2.46%)Earnings
- Q2 2021 Novo Nordisk A/S Earnings Call TranscriptAug 04, 2021kr305.5 (+4.78%)Earnings
- Novo Nordisk A/S R&D Investor Call TranscriptJun 28, 2021
- Novo Nordisk A/S Approval of Wegovyâ„¢ in the United States Investor Call TranscriptJun 07, 2021
- Novo Nordisk A/S to Discuss International Operations Call TranscriptMay 21, 2021
- Q1 2021 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptMay 06, 2021kr227.8 (-0.79%)Earnings
- Q1 2021 Novo Nordisk A/S Earnings Call TranscriptMay 05, 2021kr229.63 (+0.35%)Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 25, 2021
- Q4 2020 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptFeb 05, 2021kr220.2 (-0.96%)Earnings
- Q4 2020 Novo Nordisk A/S Earnings Call TranscriptFeb 03, 2021kr225 (+2.74%)Earnings
- Novo Nordisk A/S at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2021
- Novo Nordisk A/S to Announce the Decision to Enter the Phase 3 Development in Alzheimer's Disease with Oral Semaglutide Call TranscriptDec 16, 2020
- Novo Nordisk A/S ESG Conference Call TranscriptNov 30, 2020
- Q3 2020 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptNov 02, 2020kr208.35 (+1.50%)Earnings
- Q3 2020 Novo Nordisk A/S Earnings Call TranscriptOct 30, 2020kr205.28 (-3.41%)Earnings
- Novo Nordisk A/S to Discuss Updated 2020 Outlook Call TranscriptOct 09, 2020
- Q2 2020 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptAug 07, 2020kr203.38 (+1.59%)Earnings
- Q2 2020 Novo Nordisk A/S Earnings Call TranscriptAug 06, 2020kr200.2 (-1.81%)Earnings
- Novo Nordisk A/S Virtual R&D Investor Call (Q&A) TranscriptJun 19, 2020
- Novo Nordisk A/S Virtual R&D Investor Presentation TranscriptJun 19, 2020
- Novo Nordisk A/S at UBS Global Healthcare Conference (Virtual) TranscriptMay 20, 2020
- Q1 2020 Novo Nordisk A/S Earnings Presentation TranscriptMay 07, 2020
- Q1 2020 Novo Nordisk A/S Earnings Call TranscriptMay 06, 2020kr216.35 (+0.60%)Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 26, 2020
- Q4 2019 Novo Nordisk A/S Earnings Presentation TranscriptFeb 06, 2020
- Q4 2019 Novo Nordisk A/S Earnings Call TranscriptFeb 05, 2020kr217.5 (+4.58%)Earnings
- Novo Nordisk A/S at JPMorgan Healthcare Conference TranscriptJan 14, 2020
- Novo Nordisk A/S Capital Markets Day TranscriptNov 20, 2019
- Dicerna Pharmaceuticals Inc to Discuss Collaboration with Novo Nordisk A/S Conference Call TranscriptNov 18, 2019
- Q3 2019 Novo Nordisk A/S Earnings Presentation TranscriptNov 04, 2019
- Q3 2019 Novo Nordisk A/S Earnings Call TranscriptNov 01, 2019kr189.45 (+3.57%)Earnings
- Novo Nordisk A/S to Discuss Rybelsus® US Approval Call TranscriptSep 23, 2019
- Q2 2019 Novo Nordisk A/S Earnings Presentation TranscriptAug 12, 2019
- Q2 2019 Novo Nordisk A/S Earnings Call TranscriptAug 09, 2019kr167 (-0.24%)Earnings
- Novo Nordisk A/S Investor and Analyst Event at ADA 2019 TranscriptJun 10, 2019
- Q1 2019 Novo Nordisk A/S Earnings Presentation TranscriptMay 07, 2019
- Q1 2019 Novo Nordisk A/S Earnings Call TranscriptMay 03, 2019kr158.68 (-2.97%)Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 21, 2019
Novo Nordisk A/S Capital Markets Day Transcript
Mar 07, 2024 / 08:00AM GMT
Release Date Price:
kr919.6
(+8.33%)
Lars Fruergaard Jorgensen;S;President
Novo Nordisk A;CEO & Member of Management Board
/- -
A very warm welcome to the Novo Nordisk 2024 Capital Markets Day. My name is Lars Fruergaard Jorgensen. And together with my management team, I'm very excited about hosting all of you here today. We're excited because of our unprecedented growth. We're excited about the strategies, the progress we're making in building capacity, expanding our pipeline to sustain a very attractive growth going forward. And this is obviously all about serving more patients, and we believe we can serve many more patients in the future. We would like to start the meeting by actually inviting an individual who has been on in one of our trials to learn a bit more about what it means living with obesity and also heart failure.
So [Isabel Davis], please join me here on stage. Please. So Isabel, thank you so much for joining us today and accepting to share a bit with us your experiences. And I would like to ask you by helping us to understand what does it mean to live with obesity and
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers